The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Official Title: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Study ID: NCT05768711
Brief Summary: Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Detailed Description: AVENHIR trial is an open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of the combination of Azacitidine and Venetoclax in newly diagnosed, hypomethylating agent-naïve, higher-risk chronic myelomonocytic leukemia patients
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHU d'Amiens, Amiens, , France
CHU d'Angers, Angers, , France
Hôpital Avicenne, Bobigny, , France
CHU de Grenoble, Grenoble, , France
CHRU de Limoges, Limoges, , France
Institut Paoli Calmettes, Marseille, , France
CHU de Montpellier - Hôpital Saint Eloi, Montpellier, , France
CHU Hôtel Dieu, Nantes, , France
Hôpital privé du Confluent SAS, Nantes, , France
Hôpital Archet 1, Nice, , France
Hôpital Saint Louis, Paris, , France
Hôpital Cochin, Paris, , France
Centre hospitalier Lyon sud, Pierre-Bénite, , France
CHU de Poitiers, Poitiers, , France
Hôpital Pontchaillou, Rennes, , France
Centre Henri Becquerel, Rouen, , France
IUCT oncopole, Toulouse, , France
CHU de Tours - Hôpital Bretonneau, Tours, , France
Institut Gustave Roussy, Villejuif, , France
Name: Raphaël ITZYKSON, MD/PhD
Affiliation: Hôpital Saint Louis
Role: PRINCIPAL_INVESTIGATOR
Name: Pierre FENAUX, MD/PhD
Affiliation: Hôpital Saint Louis
Role: PRINCIPAL_INVESTIGATOR